Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Explore this paper's citation graph
Summary
The combination of ramucirumab with pac litaxel significantly increases overall survival compared with placebo plus paclitaxel, and could be regarded as a new standard second-line treatment for patients with advanced gastric cancer.
- Type
- article
- Published
- 2014-10-01
- Cited by
- 2,148
- References
- 33
- OpenAlex
- https://openalex.org/W2111237964
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:109302
Keywords
Ramucirumab, Medicine, Placebo, Paclitaxel, Internal medicine
References
- Interpreting the significance of changes in health-related quality-of-life scores.
- Asymmetric group sequential boundaries for monitoring clinical trials
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
- Modeling valuations for EuroQol health states.
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
- Phase II study of paclitaxel in pretreated advanced gastric cancer
- Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model.
- Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer
- Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
- Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
- Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
- Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel.
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
- Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
- Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
- Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.
Cited by
- Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer
- Phase 2 Study of MK-2206, an Allosteric Inhibitor of AKT, as Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer: A SWOG Cooperative Group Trial (S1005)
- Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma
- Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
- Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
- Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer.
- The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1.
- Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience
- Gastric cancer management: Kinases as a target therapy
- A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer
- VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis
- Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge?
- Strategies targeting angiogenesis in advanced non-small cell lung cancer
- Esophageal squamous cell carcinoma and adenocarcinoma: At the Gates of Mordor.
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
- Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients
- Augmentation of nab-paclitaxel chemotherapy response by mechanistically diverse antiangiogenic agents in preclinical gastric cancer models
- KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
- Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis
- Antikörper punktet bei Magenkarzinom
Related papers
- [Case Report of Four Patients Received Ramucirumab Monotherapy as Second-Line Chemotherapy for Advanced Gastric Cancer].
- Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer.
- Результаты применения рамуцирумаба в монорежиме или в комбинации с паклитакселом во второй линии лечения больных диссеминированной HER2-негативной аденокарциномой желудка или кардиоэзофагеального перехода. Опыт национального медицинского исследовательского центра онкологии им. Н.Н. Блохина
- Ramucirumab takes steps forward in gastric cancer.
- Ramucirumab: A Review in Advanced Gastric Cancer
- Ramucirumab: Boon or bane.
- REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE
- Anti-angiogenic agent ramucirumab: meaningful or marginal?
- Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
- Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma